Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: Strategies and industrial perspectives

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 168-183

  Pawar, Vivek K ^a   Meher, Jaya Gopal ^a   Singh, Yuvraj ^a   Chaurasia, Mohini ^b   Surendar Reddy, B ^c   Chourasia, Manish K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b AMITY UNIVERSITY   (India)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Gastrointestinal barriers; Oral delivery; Peptide; Proteins; Targeted delivery; Transport pathways

Indexed keywords

EMULSIONS; INDUSTRIAL RESEARCH; LIPOSOMES; PEPTIDES;

ENVIRONMENTAL CONDITIONS; GASTROINTESTINAL BARRIERS; GASTROINTESTINAL TRACT; INDUSTRIAL PRACTICES; ORAL DELIVERY; SITE-SPECIFIC MUTAGENESIS; TARGETED DELIVERY; TRANSPORT PATHWAYS;

PROTEINS;

DRUG CARRIER; LIPOSOME; NANOPARTICLE; PEPTIDES AND PROTEINS; PRODRUG; RECEPTOR; PEPTIDE; PROTEIN;

BIOTECHNOLOGY; CELL TRANSPORT; CHEMICAL REACTION; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; GASTROINTESTINAL TRACT; GLYCOSYLATION; MICROEMULSION; MUTAGENESIS; NANOEMULSION; PEGYLATION; PH; PROTEINYLATION; REVIEW; ACTIVE TRANSPORT; ANIMAL; GASTROINTESTINAL DISEASES; HUMAN; MEDICINAL CHEMISTRY; METABOLISM;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; PEPTIDES; PROTEINS;

EID: 84908221805     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.031     Document Type: Review

References (187)

1. A. Sasson Biotechnologies: current achievements and prospects social acceptance of biotechnology-derived products CHAPTER 14 2004 1 157
2. A. Sasson Medical Biotechnology: Achievements, Prospects and Perceptions 2005 United Nations Univ. Press
3. D.M. Prazeres, G.N. Ferreira, G.A. Monteiro, C.L. Cooney, and J. Cabral Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks Trends Biotechnol. 17 1999 169 174
4. J.K. Ma, P.M. Drake, and P. Christou The production of recombinant pharmaceutical proteins in plants Nat. Rev. Genet. 4 2003 794 805
5. P.A. Patten, R.J. Howard, and W.P. Stemmer Applications of DNA shuffling to pharmaceuticals and vaccines Curr. Opin. Biotechnol. 8 1997 724 733
6. J. Renukuntla, A.D. Vadlapudi, A. Patel, S.H. Boddu, and A.K. Mitra Approaches for enhancing oral bioavailability of peptides and proteins Int. J. Pharm. 447 2013 75 93
7. V. Marx Watching peptide drugs grow up Chem. Eng. News 83 2005 17 24
8. C.M. Van Itallie, J. Holmes, A. Bridges, J.L. Gookin, M.R. Coccaro, W. Proctor, O.R. Colegio, and J.M. Anderson The density of small tight junction pores varies among cell types and is increased by expression of claudin-2 J. Cell Sci. 121 2008 298 305
9. J.L. Madara Regulation of the movement of solutes across tight junctions Annu. Rev. Physiol. 60 1998 143 159
10. R.D. Broadwell Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal Acta Neuropathol. 79 1989 117 128
11. H. Hillaireau, and P. Couvreur Nanocarriers' entry into the cell: relevance to drug delivery Cell. Mol. Life Sci. 66 2009 2873 2896
12. A.T. Florence Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov. Today Technol. 2 2005 75 81
13. M.-C. Chen, K. Sonaje, K.-J. Chen, and H.-W. Sung A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery Biomaterials 32 2011 9826 9838
14. I. Knütter, C. Wollesky, G. Kottra, M.G. Hahn, W. Fischer, K. Zebisch, R.H.H. Neubert, H. Daniel, and M. Brandsch Transport of angiotensin-converting enzyme inhibitors by H +/peptide transporters revisited J. Pharmacol. Exp. Ther. 327 2008 432 441
15. E. Nakashima, A. Tsuji, S. Kagatani, and T. Yamana Intestinal absorption mechanism of amino-beta-lactam antibiotics. III. Kinetics of carrier-mediated transport across the rat small intestine in situ J. Pharmacobiodyn 7 1984 452 464
16. M. Grenson The utilization of exogenous pyrimidines and the recycling of uridine-5′-phosphate derivatives in Saccharomyces cerevisiae, as studied by means of mutants affected in pyrimidine uptake and metabolism Eur. J. Biochem. 11 1969 249 260
17. G.J. Russell-Jones The potential use of receptor-mediated endocytosis for oral drug delivery Adv. Drug Deliv. Rev. 46 2001 59 73
18. W.N. Charman, and C.J.H. Porter Lipophilic prodrugs designed for intestinal lymphatic transport Adv. Drug Deliv. Rev. 19 1996 149 169
19. S.D. Conner, and S.L. Schmid Regulated portals of entry into the cell Nature 422 2003 37 44
20. J. Boyle Lehninger principles of biochemistry D. Nelson, M. Cox, 4th ed. Biochem Mol Biol Edu 33 2005 74 75
21. A. Ozgur, and Y. Tutar Therapeutic proteins: a to z Protein Pept. Lett. 20 2013 1365 1372
22. D.J. Brayden, and D.J. O'Mahony Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines Pharm. Sci. Technol. Today 1 1998 291 299
23. Y. Yun, Y.W. Cho, and K. Park Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery Adv. Drug Deliv. Rev. 65 2013 822 832
24. L.M. Ensign, R. Cone, and J. Hanes Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers Adv. Drug Deliv. Rev. 64 2012 557 570
25. S.J. Shire, Z. Shahrokh, and J. Liu Challenges in the development of high protein concentration formulations J. Pharm. Sci. 93 2004 1390 1402
26. W. Wang Instability, stabilization, and formulation of liquid protein pharmaceuticals Int. J. Pharm. 185 1999 129 188
27. M. Lai, and E. Topp Solid-state chemical stability of proteins and peptides J. Pharm. Sci. 88 1999 489 500
28. E.Y. Chi, S. Krishnan, T.W. Randolph, and J.F. Carpenter Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation Pharm. Res. 20 2003 1325 1336
29. S. Frokjaer, and D.E. Otzen Protein drug stability: a formulation challenge Nat. Rev. Drug Discov. 4 2005 298 306
30. D.F. Veber, and R.M. Freidinger The design of metabolically-stable peptide analogs Trends Neurosci. 8 1985 392 396
31. D. Roemer, and J. Pless Structure activity relationship of orally active enkephalin analogues as analgesics Life Sci. 24 1979 621 624
32. O.S. Gudmundsson, S.D.S. Jois, D.G.V. Velde, T.J. Siahaan, R.T. Borchardt, and B. Wang The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides J. Pept. Res. 53 1999 383 392
33. P. Vlieghe, V. Lisowski, J. Martinez, and M. Khrestchatisky Synthetic therapeutic peptides: science and market Drug Discov. Today 15 2010 40 56
34. J. Chatterjee, B. Laufer, and H. Kessler Synthesis of N-methylated cyclic peptides Nat. Protoc. 7 2012 432 444
35. J.M. Humphrey, and A.R. Chamberlin Chemical synthesis of natural product peptides: coupling methods for the incorporation of noncoded amino acids into peptides Chem. Rev. 97 1997 2243 2266
36. J.A. Patch, and A.E. Barron Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers Curr. Opin. Chem. Biol. 6 2002 872 877
37. W.F. DeGrado, J.P. Schneider, and Y. Hamuro The twists and turns of β-peptides J. Pept. Res. 54 1999 206 217
38. S. Gupta, and J.W. Payne Evaluation of the conformational propensities of peptide isosteres as a basis for selecting bioactive pseudopeptides J. Pept. Res. 58 2001 546 561
39. G.M. Pauletti, S. Gangwar, T.J. Siahaan, A. Jeffrey, and R.T. Borchardt Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies Adv. Drug Deliv. Rev. 27 1997 235 256
40. T. Godballe, L.L. Nilsson, P.D. Petersen, and H. Jenssen Antimicrobial β-peptides and α-peptoids Chem. Biol. Drug Des. 77 2011 107 116
41. J. Seo, G. Ren, H. Liu, Z. Miao, M. Park, Y. Wang, T.M. Miller, A.E. Barron, and Z. Cheng In vivo Biodistribution and small animal PET of 64Cu-labeled antimicrobial peptoids Bioconjug. Chem. 23 2012 1069 1079
42. O. Ovadia, Y. Linde, C. Haskell-Luevano, M.L. Dirain, T. Sheynis, R. Jelinek, C. Gilon, and A. Hoffman The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm Bioorg. Med. Chem. 18 2010 580 589
43. Y. Wang, H. Lin, R. Tullman, C.F. Jewell, M.L. Weetall, and F.L.S. Tse Absorption and disposition of a tripeptoid and a tetrapeptide in the rat Biopharm. Drug Dispos. 20 1999 69 75
44. P. Varamini, F.M. Mansfeld, J.T. Blanchfield, B.D. Wyse, M.T. Smith, and I. Toth Synthesis and biological evaluation of an orally active glycosylated endomorphin-1 J. Med. Chem. 55 2012 5859 5867
45. M. Nomoto, K. Yamada, M. Haga, and M. Hayashi Improvement of intestinal absorption of peptide drugs by glycosylation: transport of tetrapeptide by the sodium ion-dependent d-glucose transporter J. Pharm. Sci. 87 1998 326 332
46. R.C. Ladner, A.K. Sato, J. Gorzelany, and M. de Souza Phage display-derived peptides as therapeutic alternatives to antibodies Drug Discov. Today 9 2004 525 529
47. Y. Nojima, Y. Suzuki, K. Iguchi, T. Shiga, A. Iwata, T. Fujimoto, K. Yoshida, H. Shimizu, T. Takeuchi, and A. Sato Development of poly(ethylene glycol) conjugated lactoferrin for oral administration Bioconjug. Chem. 19 2008 2253 2259
48. Z.X. Zhang, Y.K. Liu, H. Pan, L. Pan, Q. Zhang, H.M. Su, Q.L. Zhao, H. Li, and C. He The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats Growth Hormon. IGF Res. 22 2012 30 35
49. Y.S. Youn, J.Y. Jung, S.H. Oh, S.D. Yoo, and K.C. Lee Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy J. Control. Release 114 2006 334 342
50. Y.S. Youn, D.H. Na, and K.C. Lee High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation J. Control. Release 117 2007 371 379
51. P. Calceti, S. Salmaso, G. Walker, and A. Bernkop-Schnürch Development and in vivo evaluation of an oral insulin-PEG delivery system Eur. J. Pharm. Sci. 22 2004 315 323
52. R.B. Pepinsky, D.J. LePage, A. Gill, A. Chakraborty, S. Vaidyanathan, M. Green, D.P. Baker, E. Whalley, P.S. Hochman, and P. Martin Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity J. Pharmacol. Exp. Ther. 297 2001 1059 1066
53. G.M. Pauletti, S. Gangwar, G.T. Knipp, M.M. Nerurkar, F.W. Okumu, K. Tamura, T.J. Siahaan, and R.T. Borchardt Structural requirements for intestinal absorption of peptide drugs J. Control. Release 41 1996 3 17
54. S. Gangwar, G.M. Pauletti, B. Wang, T.J. Siahaan, V.J. Stella, and R.T. Borchardt Prodrug strategies to enhance the intestinal absorption of peptides Drug Discov. Today 2 1997 148 155
55. F. Li, H. Maag, and T. Alfredson Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting J. Pharm. Sci. 97 2008 1109 1134
56. D. Gupta, S. Varghese Gupta, A. Dahan, Y. Tsume, J. Hilfinger, K.-D. Lee, and G.L. Amidon Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue Mol. Pharm. 10 2012 512 522
57. R.S. Talluri, S.K. Samanta, R. Gaudana, and A.K. Mitra Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir Int. J. Pharm. 361 2008 118 124
58. Y. Zhang, J. Sun, Y. Gao, L. Jin, Y. Xu, H. Lian, Y. Sun, Y. Sun, J. Liu, R. Fan, T. Zhang, and Z. He A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine Mol. Pharm. 10 2013 3195 3202
59. H. Ouyang, W. Chen, T.E. Andersen, B. Steffansen, and R.T. Borchardt Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): part I. Role of efflux transporters in the intestinal mucosa J. Pharm. Sci. 98 2009 337 348
60. H. Ouyang, W. Chen, T.E. Andersen, B. Steffansen, and R.T. Borchardt Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): part II. Role of metabolic enzymes in the intestinal mucosa J. Pharm. Sci. 98 2009 349 361
61. R. Nofsinger, T. Fuchs-Knotts, and R.T. Borchardt Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 3: synthesis of analogs designed to have improved stability to oxidative metabolism J. Pharm. Sci. 101 2012 3486 3499
62. R. Nofsinger, and R.T. Borchardt Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa J. Pharm. Sci. 101 2012 3500 3510
63. A. Ezra, A. Hoffman, E. Breuer, I.S. Alferiev, J. Mönkkönen, N. El Hanany-Rozen, G. Weiss, D. Stepensky, I. Gati, H. Cohen, S. Törmälehto, G.L. Amidon, and G. Golomb A peptide prodrug approach for improving bisphosphonate oral absorption J. Med. Chem. 43 2000 3641 3652
64. A. Lalatsa, V. Lee, J.P. Malkinson, M. Zloh, A.G. Schätzlein, and I.F. Uchegbu A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine5-enkephalin, to the brain Mol. Pharm. 9 2012 1665 1680
65. M.K. Marschütz, W. Zauner, F. Mattner, A. Otava, M. Buschle, and A. Bernkop-Schnürch Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration Peptides 23 2002 1727 1733
66. O. Ovadia, S. Greenberg, J. Chatterjee, B. Laufer, F. Opperer, H. Kessler, C. Gilon, and A. Hoffman The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides Mol. Pharm. 8 2011 479 487
67. E. Biron, J. Chatterjee, O. Ovadia, D. Langenegger, J. Brueggen, D. Hoyer, H.A. Schmid, R. Jelinek, C. Gilon, A. Hoffman, and H. Kessler Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues Angew. Chem. Int. Ed. 47 2008 2595 2599
68. N. Gong, A.-N. Ma, L.-J. Zhang, X.-S. Luo, Y.-H. Zhang, M. Xu, and Y.-X. Wang Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity Br. J. Pharmacol. 163 2011 399 412
69. E.P. Herrero, M.J. Alonso, and N. Csaba Polymer-based oral peptide nanomedicines Ther. Deliv. 3 2012 657 668
70. E. Scott Swenson, and W.J. Curatolo (C) Means to enhance penetration: (2) intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity Adv. Drug Deliv. Rev. 8 1992 39 92
71. K. Whitehead, N. Karr, and S. Mitragotri Safe and effective permeation enhancers for oral drug delivery Pharm. Res. 25 2008 1782 1788
72. E.S. Swenson, W. Milisen, and W. Curatolo Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility Pharm. Res. 11 1994 1132 1142
73. A. Bernkop-Schnurch, C.E. Kast, and D. Guggi Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems J. Control. Release 93 2003 95 103
74. J.R. Pappenheimer Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters J. Membr. Biol. 100 1987 137 148
75. G. Fricker, A. Fahr, C. Beglinger, T. Kissel, G. Reiter, and J. Drewe Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations Br. J. Pharmacol. 117 1996 217 223
76. M.E. Lane, C.M. O'Driscoll, and O.I. Corrigan Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model J. Pharm. Pharmacol. 57 2005 169 175
77. P. Sharma, M.V.S. Varma, H.P.S. Chawla, and R. Panchagnula Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers Farmaco 60 2005 884 893
78. M.A. Karsdal, K. Henriksen, A.C. Bay-Jensen, B. Molloy, M. Arnold, M.R. John, I. Byrjalsen, M. Azria, B.J. Riis, P. Qvist, and C. Christiansen Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials J. Clin. Pharmacol. 51 2011 460 471
79. S. Maher, and D.J. Brayden Overcoming poor permeability: translating permeation enhancers for oral peptide delivery Drug Discov. Today Technol. 9 2012 e113 e119
80. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572
81. Y. Maitani, and Y. Hattori Oligoarginine-PEG-lipid particles for gene delivery Expert Opin. Drug Deliv. 6 2009 1065 1077
82. Y.-L. Tseng, J.-J. Liu, and R.-L. Hong Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and Tat: a kinetic and efficacy study Mol. Pharmacol. 62 2002 864 872
83. B. Christiaens, J. Grooten, M. Reusens, A. Joliot, M. Goethals, J. Vandekerckhove, A. Prochiantz, and M. Rosseneu Membrane interaction and cellular internalization of penetratin peptides Eur. J. Biochem. 271 2004 1187 1197
84. E. Bárány-Wallje, S. Keller, S. Serowy, S. Geibel, P. Pohl, M. Bienert, and M. Dathe A critical reassessment of penetratin translocation across lipid membranes Biophys. J. 89 2005 2513 2521
85. P.E.G. Thorén, D. Persson, P. Isakson, M. Goksör, A. Önfelt, and B. Nordén Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells Biochem. Biophys. Res. Commun. 307 2003 100 107
86. N. Kamei, M. Morishita, J. Ehara, and K. Takayama Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery J. Control. Release 131 2008 94 99
87. N. Kamei, M. Morishita, and K. Takayama Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides J. Control. Release 136 2009 179 186
88. M. Morishita, N. Kamei, J. Ehara, K. Isowa, and K. Takayama A novel approach using functional peptides for efficient intestinal absorption of insulin J. Control. Release 118 2007 177 184
89. S. El- Andaloussi, P. Jarver, H.J. Johansson, and U. Langel Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study Biochem. J. 407 2007 285 292
90. K. Saar, M. Lindgren, M. Hansen, E. Eiríksdóttir, Y. Jiang, K. Rosenthal-Aizman, M. Sassian, and Ü. Langel Cell-penetrating peptides: a comparative membrane toxicity study Anal. Biochem. 345 2005 55 65
91. K. Kilk, R. Mahlapuu, U. Soomets, and Ü. Langel Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling Toxicology 265 2009 87 95
92. M.R. Rekha, and C.P. Sharma Oral delivery of therapeutic protein/peptide for diabetes - future perspectives Int. J. Pharm. 440 2013 48 62
93. G.P. Carino, and E. Mathiowitz Oral insulin delivery Adv. Drug Deliv. Rev. 35 1999 249 257
94. A. Bernkop-Schnürch The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins J. Control. Release 52 1998 1 16
95. M. Hussain, M.L. Lim, K. Raghavan, N. Rogers, R. Hidalgo, and C. Kettner A phosphinic acid dipeptide analogue to stabilize peptide drugs during their intranasal absorption Pharm. Res. 9 1992 626 628
96. R.M. McConnell, D. Frizzell, A. Camp, A. Evans, W. Jones, and C. Cagle New pepstatin analogs: synthesis and pepsin inhibition J. Med. Chem. 34 1991 2298 2300
97. A. Fjellestad-Paulsen, L. d'Agay-Abensour, P. Höglund, and J.C. Rambaud Bioavailability of 1-deamino-8-d-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers Eur. J. Clin. Pharmacol. 50 1996 491 495
98. M.K. Marschütz, and A. Bernkop-Schnürch Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro Biomaterials 21 2000 1499 1507
99. F.-Y. Su, K.-J. Lin, K. Sonaje, S.-P. Wey, T.-C. Yen, Y.-C. Ho, N. Panda, E.-Y. Chuang, B. Maiti, and H.-W. Sung Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery Biomaterials 33 2012 2801 2811
100. D. Friedman, and G. Amidon Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of Leu-enkephalin and analogues Pharm. Res. 8 1991 93 96
101. S. Şenel, and A.A. HIncal Drug permeation enhancement via buccal route: possibilities and limitations J. Control. Release 72 2001 133 144
102. D.H. Oh, K.H. Chun, S.O. Jeon, J.W. Kang, and S. Lee Enhanced transbuccal salmon calcitonin (sCT) delivery: effect of chemical enhancers and electrical assistance on in vitro sCT buccal permeation Eur. J. Pharm. Biopharm. 79 2011 357 363
103. C.Y. Cui, W.L. Lu, L. Xiao, S.Q. Zhang, Y.B. Huang, S.L. Li, R.J. Zhang, G.L. Wang, X. Zhang, and Q. Zhang Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity Biol. Pharm. Bull. 28 2005 2279 2288
104. J. Mannila, K. Jarvinenb, J. Holappaa, L. Matilainena, S. Auriolaa, and P. Jarhoa Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: a study using cyclosporin A, α-cyclodextrin and quaternary chitosan N-betainate Int. J. Pharm. 381 2009 19 24
105. P. Modi, M. Mihic, and A. Lewin The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System Diabetes Metab. Res. 18 Suppl. 1 2002 S38 S42
106. G. Bernstein Delivery of insulin to the buccal mucosa utilizing the RapidMist system Expert Opin. Drug Deliv. 5 2008 1047 1055
107. D. Guggi, A.H. Krauland, and A.B. Schnurch Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin J. Control. Release 92 2003 125 135
108. G. Borchard, H.L. Lueβen, A.G. de Boer, J.C. Verhoef, C.-M. Lehr, and H.E. Junginger The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro J. Control. Release 39 1996 131 138
109. I. Behrens, A.I. Pena, M.J. Alonso, and T. Kissel Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport Pharm. Res. 19 2002 1185 1193
110. H.J. Lee, and G.L. Amidon The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats Biopharm. Drug Dispos. 23 2002 131 141
111. M. Tobio, A. Sanchez, A. Vila, I.I. Soriano, C. Evora, J.L. Vila-Jato, and M.J. Alonso The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration Colloids Surf. B: Biointerfaces 18 2000 315 323
112. X. Li, S. Guo, C. Zhu, Q. Zhu, Y. Gan, J. Rantanen, U.L. Rahbek, L. Hovgaard, and M. Yang Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles Biomaterials 34 2013 9678 9687
113. P. He, H. Liu, Z. Tang, M. Deng, Y. Yang, X. Pang, and X. Chen Poly(ester amide) blend microspheres for oral insulin delivery Int. J. Pharm. 455 2013 259 266
114. H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, and Y. Kawashima Mucoadhesion of polymer-coated liposomes to rat intestine in vitro Chem. Pharm. Bull. 42 1994 1954 1956
115. Y. Kawashima, H. Yamamoto, H. Takeuchi, and Y. Kuno Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin Pharm. Dev. Technol. 5 2000 77 85
116. A. Vila, A. Sanchez, M. Tobio, P. Calvo, and M.J. Alonso Design of biodegradable particles for protein delivery J. Control. Release 78 2002 15 24
117. V. Gupta, B.H. Hwang, J. Lee, A.C. Anselmo, N. Doshi, and S. Mitragotri Mucoadhesive intestinal devices for oral delivery of salmon calcitonin J. Control. Release 172 2013 753 762
118. J. Hunter, and B.H. Hirst Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption Adv. Drug Deliv. Rev. 25 1997 129 157
119. S. Khandavilli, and R. Panchagnula Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats J. Invest. Dermatol. 127 2006 154 162
120. K. Yin Win, and S.-S. Feng Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2005 2713 2722
121. N. Zheng, L. Yin, Z. Song, L. Ma, H. Tang, N.P. Gabrielson, H. Lu, and J. Cheng Maximizing gene delivery efficiencies of cationic helical polypeptides via balanced membrane penetration and cellular targeting Biomaterials 35 2013 1302 1314
122. H. Tozaki, Y. Emi, E. Horisaka, T. Fujita, A. Yamamoto, and S. Muranishi Metabolism of peptide drugs by the microorganisms in rat cecal contents Biol. Pharm. Bull. 18 1995 929 931
123. H. Tozaki, J. Nishioka, J. Komoike, N. Okada, T. Fujita, S. Muranishi, S.I. Kim, H. Terashima, and A. Yamamoto Enhanced absorption of insulin and (Asu(1,7))eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery J. Pharm. Sci. 90 2001 89 97
124. L. Yang, J.S. Chu, and J.A. Fix Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation Int. J. Pharm. 235 2002 1 15
125. R.S. Geary, and H. Wade Schlameus Vancomycin and insulin used as models for oral delivery of peptides J. Control. Release 23 1993 65 74
126. W. Paul, and C.P. Sharma Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study J. Pharm. Sci. 97 2008 875 882
127. H.-W. Sung, K. Sonaje, Z.-X. Liao, L.-W. Hsu, and E.-Y. Chuang pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications Acc. Chem. Res. 45 2012 619 629
128. A. Lalatsa, N.L. Garrett, T. Ferrarelli, J. Moger, A.G. Schätzlein, and I.F. Uchegbu Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharm. 9 2012 1764 1774
129. S.K. Kim, J. Huh, S.Y. Kim, Y. Byun, D.Y. Lee, and H.T. Moon Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery Bioconjug. Chem. 22 2011 1451 1458
130. B. Sarmento, A. Ribeiro, F. Veiga, D. Ferreira, and R. Neufeld Oral bioavailability of insulin contained in polysaccharide nanoparticles Biomacromolecules 8 2007 3054 3060
131. S. Hong, S. Yum, H.-J. Yoo, S. Kang, J.-H. Yoon, D. Min, Y.M. Kim, and Y. Jung Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis Mol. Pharm. 9 2012 1310 1319
132. W. Situ, L. Chen, X. Wang, and X. Li Resistant starch film-coated microparticles for an oral colon-specific polypeptide delivery system and its release behaviors J. Agric. Food Chem. 62 2014 3599 3609
133. Y. Ren, X. Shi, Q. Sun, and L. Sun Dual-controlled oral colon-targeted delivery of bovine insulin based on mesoporous phosphonate Mater. Res. Bull. 48 2013 4850 4855
134. S. Şenel, M.J. Kremer, S. Kaş, P.W. Wertz, A.A. HIncal, and C.A. Squier Enhancing effect of chitosan on peptide drug delivery across buccal mucosa Biomaterials 21 2000 2067 2071
135. N. Langoth, H. Kahlbacher, G. Schöffmann, I. Schmerold, M. Schuh, S. Franz, P. Kurka, and A. Bernkop-Schnürch Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system Pharm. Res. 23 2006 573 579
136. R.E. Stratford Jr., and V.H.L. Lee Aminopeptidase activity in homogenates of various absorptive mucosae m the albino rabbit: implications in peptide delivery Int. J. Pharm. 30 1986 73 82
137. H.P. Merkle, and G. Wolany Buccal delivery for peptide drugs J. Control. Release 21 1992 155 164
138. D. Torres, M. Rodriguez, and M. CUNA Microencapsulated lipid cores for site-specific delivery of corticosteroid and peptide drugs to the colonic region STP Pharma. Sci. 13 2003 49 56
139. B.J. Aungst Intestinal permeation enhancers J. Pharm. Sci. 89 2000 429 442
140. G. Fetih, H. Fausia, N. Okada, T. Fujita, M. Attia, and A. Yamamoto Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats J. Drug Target. 14 2006 165 172
141. H. Tozaki, J. Komoike, C. Tada, T. Maruyama, A. Terabe, T. Suzuki, A. Yamamoto, and S. Muranishi Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon J. Pharm. Sci. 86 1997 1016 1021
142. K. Tahara, S. Samura, K. Tsuji, H. Yamamoto, Y. Tsukada, Y. Bando, H. Tsujimoto, R. Morishita, and Y. Kawashima Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(d, l-lactide-co-glycolide) nanospheres for inflammatory bowel disease Biomaterials 32 2011 870 878
143. M.-K. Yoo, S.-K. Kang, J.-H. Choi, I.-K. Park, H.-S. Na, H.-C. Lee, E.-B. Kim, N.-K. Lee, J.-W. Nah, Y.-J. Choi, and C.-S. Cho Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique Biomaterials 31 2010 7738 7747
144. X. Gao, T. Wang, B. Wu, J. Chen, J. Chen, Y. Yue, N. Dai, H. Chen, and X. Jiang Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles Biochem. Biophys. Res. Commun. 377 2008 35 40
145. D. Shah, and W.C. Shen Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells J. Pharm. Sci. 85 1996 1306 1311
146. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J.X. Xiao, and T. Kissel Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50 2000 147 160
147. D. Lochmann, E. Jauk, and A. Zimmer Drug delivery of oligonucleotides by peptides Eur. J. Pharm. Biopharm. 58 2004 237 251
148. L. Pelkmans, and A. Helenius Endocytosis via caveolae Traffic 3 2002 311 320
149. G. Sahay, D.Y. Alakhova, and A.V. Kabanov Endocytosis of nanomedicines J. Control. Release 145 2010 182 195
150. S. Jain, V.V. Rathi, A.K. Jain, M. Das, and C. Godugu Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin Nanomedicine 7 2012 1311 1337
151. K.B. Chalasani, G.J. Russell-Jones, S.K. Yandrapu, P.V. Diwan, and S.K. Jain A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin J. Control. Release 117 2007 421 429
152. K.B. Chalasani, G.J. Russell-Jones, A.K. Jain, P.V. Diwan, and S.K. Jain Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles J. Control. Release 122 2007 141 150
153. N. Zhang, Q. Ping, G. Huang, W. Xu, Y. Cheng, and X. Han Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin Int. J. Pharm. 327 2006 153 159
154. G.J. Russell-Jones, H. Veitch, and L. Arthur Lectin-mediated transport of nanoparticles across Caco-2 and OK cells Int. J. Pharm. 190 1999 165 174
155. V. Fievez, L. Plapied, A. des Rieux, V. Pourcelle, H. Freichels, V. Wascotte, M.-L. Vanderhaeghen, C. Jerôme, A. Vanderplasschen, J. Marchand-Brynaert, Y.-J. Schneider, and V. Préat Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination Eur. J. Pharm. Biopharm. 73 2009 16 24
156. Y. Yin, D. Chen, M. Qiao, Z. Lu, and H. Hu Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin J. Control. Release 116 2006 337 345
157. H.H. Salman, J.M. Irache, and C. Gamazo Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination Vaccine 27 2009 4784 4790
158. N. Normanno, A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, A. Carotenuto, G. De Feo, F. Caponigro, and D.S. Salomon Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2006 2 16
159. G. Tortora, and F. Ciardiello Anti-epidermal growth factor receptor drugs in cancer therapy Expert Opin. Investig. Drugs 11 2002 755 768
160. P. Diagaradjane, J.M. Orenstein-Cardona, N.E. Colón-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D.L. Schwartz, J.G. Gelovani, and S. Krishnan Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe Clin. Cancer Res. 14 2008 731 741
161. I.H. El-Sayed, X. Huang, and M.A. El-Sayed Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer Nano Lett. 5 2005 829 834
162. Q. Yuan, E. Lee, W.A. Yeudall, and H. Yang Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery Oral Oncol. 46 2010 698 704
163. P. Magadala, and M. Amiji Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells AAPS J. 10 2008 565 576
164. Y. Zheng, Z. Cai, X. Song, Q. Chen, Y. Bi, Y. Li, and S. Hou Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies J. Drug Target. 17 2009 294 303
165. X. Liu, Y. Zhang, D. Ma, H. Tang, L. Tan, Q. Xie, and S. Yao Biocompatible multi-walled carbon nanotube-chitosan-folic acid nanoparticle hybrids as GFP gene delivery materials Colloids Surf. B: Biointerfaces 111 2013 224 231
166. P. Hurkat, A. Jain, A. Jain, S. Shilpi, A. Gulbake, and S. Jain Concanavalin A conjugated biodegradable nanoparticles for oral insulin delivery J. Nanopart. Res. 14 2012 1 14
167. J.S. Rodrigues, N.S. Santos-Magalhães, L.C.B.B. Coelho, P. Couvreur, G. Ponchel, and R. Gref Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins J. Control. Release 92 2003 103 112
168. A.L.Z. Lee, Y. Wang, W.-H. Ye, H.S. Yoon, S.Y. Chan, and Y.-Y. Yang Efficient intracellular delivery of functional proteins using cationic polymer core/shell nanoparticles Biomaterials 29 2008 1224 1232
169. Y. Jin, Y. Song, X. Zhu, D. Zhou, C. Chen, Z. Zhang, and Y. Huang Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport Biomaterials 33 2012 1573 1582
170. H. Salman, C. Gamazo, P.C. Smidt, G. Russell-Jones, and J. Irache Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B12-gantrez nanoparticles Pharm. Res. 25 2008 2859 2868
171. Y. Nagasaki, K. Yasugi, Y. Yamamoto, A. Harada, and K. Kataoka Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules Biomacromolecules 2 2001 1067 1070
172. S. Hamdy, A. Haddadi, A. Shayeganpour, J. Samuel, and A. Lavasanifar Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles Pharm. Res. 28 2011 2288 2301
173. P.N. Gupta, K. Khatri, A.K. Goyal, N. Mishra, and S.P. Vyas M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B J. Drug Target. 15 2007 701 713
174. T.E. Rajapaksa, M. Stover-Hamer, X. Fernandez, H.A. Eckelhoefer, and D.D. Lo Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery J. Control. Release 142 2010 196 205
175. H. Harde, A.K. Agrawal, and S. Jain Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery Nanomedicine 2014 10.2217/nnm.13.225
176. S. Jain, A. Indulkar, H. Harde, and A.K. Agrawal Oral mucosal immunization using glucomannosylated bilosomes J. Biomed. Nanotechnol. 10 2014 932 947
177. C. Chen, T. Fan, Y. Jin, Z. Zhou, Y. Yang, X. Zhu, Z.R. Zhang, Q. Zhang, and Y. Huang Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle-double emulsion method via the combined use of different solid lipids Nanomedicine 8 2013 1085 1100
178. M. Vandana, and S.K. Sahoo Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles Nanomedicine 4 2009 773 785
179. H. Kajal, and A. Mishra Preparation of tetanus toxoid and ovalbumin loaded gliadin nanoparticles for oral immunization J. Biomed. Nanotechnol. 7 2011 211 212
180. A.F. Soares, R.A. Carvalho, and F. Veiga Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems J. Biomed. Nanotechnol. 2 2007 183 202
181. S. Martins, A.C. Silva, D.C. Ferreira, and E.B. Souto Improving oral absorption of salmon calcitonin by trimyristin lipid nanoparticles J. Biomed. Nanotechnol. 5 2009 76 83
182. Q. Zhang, N. He, L. Zhang, F. Zhu, Q. Chen, Y. Qin, Z. Zhang, Q. Zhang, S. Wang, and Q. He The in vitro and in vivo study on self-nanoemulsifying drug delivery system (SNEDDS) based on insulin-phospholipid complex J. Biomed. Nanotechnol. 8 2012 90 97
183. Z.H. Zhang, S. Abbad, R.R. Pan, A.Y. Waddad, L.L. Hou, H.X. Lv, and J.P. Zhou N-octyl-N-arginine chitosan micelles as an oral delivery system of insulin J. Biomed. Nanotechnol. 9 2013 601 609
184. T.A. Sonia, and C.P. Sharma pH sensitive thiolated cationic hydrogel for oral insulin delivery J. Biomed. Nanotechnol. 10 2014 642 650
185. Available from: http://www.accesspharma.com/product-programs/cobalamin-mediated-oral-drug-delivery/ (Date of access: 4 August 2014)
186. Available from: http://www.aphios.com/ (Date of access: 4 August 2014)
187. R. Soltero, and E. Nnochiri The oral delivery of protein and peptide drugs Innov. Pharm. Technol. 2001 106 110 (December)